AppBrain's verdict
- Rating on App Store
- 5.00
- 3 ratings
- Last updated
- July 18, 2023
- Size
- 44.3 MB
It doesn't have enough ratings yet to judge what users think.
User feedback
Ratings and reviews on the App StoreComments on OnADose for iOS
We don't have enough comments to show example comments. Please check back later.
Store listing
By AbbVie, from the App StoreDescription by AbbVie Written by the developer, not by AppBrain. Click to read.
This app is intended for training use by US healthcare professionals ONLY. Patients should seek a doctor’s advice before making any medical decisions.
OnabotulinumtoxinA Important Safety Information
OnabotulinumtoxinA Indications
Chronic Migraine
-OnabotulinumtoxinA is indicated for the prophylaxis of headaches in adult patients with Chronic Migraine (≥ 15 days per month with headache lasting 4 hours a day or longer).
Limitations of Use
-Safety and effectiveness have not been established for the prophylaxis of episodic migraine (14 headache days or fewer per month) in 7 placebo-controlled studies.
Spasticity
-OnabotulinumtoxinA is indicated for the treatment of spasticity in patients 2 years of age and older.
Limitations of Use
-OnabotulinumtoxinA has not been shown to improve upper extremity functional abilities or range of motion at a joint affected by a fixed contracture.
Cervical Dystonia
-OnabotulinumtoxinA is indicated for the treatment of adults with Cervical Dystonia to reduce the severity of abnormal head position and neck pain associated with Cervical Dystonia.
IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING
WARNING: DISTANT SPREAD OF TOXIN EFFECT
Postmarketing reports indicate that the effects of onabotulinumtoxinA and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have an underlying condition that would predispose them to these symptoms. In unapproved uses and in approved indications, cases of spread of effect have been reported at doses comparable to those used to treat cervical dystonia and spasticity and at lower doses.
Contraindications
-Hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation
-Infection at the proposed injection site
Warnings and Precautions
-Spread of toxin effects; swallowing and breathing difficulties can lead to death. Seek immediate medical attention if respiratory, speech or swallowing difficulties occur
-Potency Units of onabotulinumtoxinA are not interchangeable with other preparations of botulinum toxin products
-Potential serious adverse reactions after onabotulinumtoxinA injections for unapproved uses
-Concomitant neuromuscular disorder may exacerbate clinical effects of treatment
-Use with caution in patients with compromised respiratory function
-Bronchitis and upper respiratory tract infections in patients treated for spasticity
Adverse Reactions
The most common adverse reactions (≥5% and >placebo, if applicable) are:
-Chronic Migraine: neck pain, headache
-Adult Spasticity: pain in extremity
-Pediatric Spasticity: upper respiratory tract infection
-Cervical Dystonia: dysphagia, upper respiratory infection, neck pain, headache, increased cough, flu syndrome, back pain, rhinitis
Drug Interactions
-Patients receiving concomitant treatment of onabotulinumtoxinA and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like agents), or muscle relaxants, should be observed closely because the effect of onabotulinumtoxinA may be potentiated
Use in Specific Populations
-Pregnancy: Based on animal data, may cause fetal harm
Please see full Prescribing Information for onabotulinumtoxinA. Available at http://www.rxabbvie.com.
Copyright ©2022 AbbVie. All rights reserved.
Safety and technology
Found in the app by AppBrain- Price
- Free
- App size
- 44.3 MB
- Content rating
- Medium
Technologies used by OnADose
Releases
Updates seen on the App Store- Version
- 1.1.0
- Launched
- December 2022
No changelog data
Alternatives
Similar apps and more from AbbVieAlternatives to OnADose
More from AbbVie
Rankings
App Store top chartsApp Store Rankings for OnADose
About the app and developer
About OnADose
OnADose is a medical app developed by AbbVie.
User Ratings
OnADose is rated 5.00 out of 5 stars. The rating is based on 3 ratings.
App Information
OnADose is freely available from the App Store. The app size is 44.30 MB. The latest version available is 1.1.0. The last update was on July 18, 2023.
Technical Requirements
The app has a content rating of Medium Maturity. The app has been available on the App Store since December 2022.
OnADose is made and published by AbbVie. AppBrain is an independent app data site and isn't affiliated with AbbVie. The app name, icon, screenshots and description belong to AbbVie and are shown as published on the App Store.
Developer information for AbbVie
Address:
Share OnADose
Subscribe now to get full and unlimited access to AppBrain Intelligence. You'll have access to:
- App Intelligence dashboard (performance timeline, competitor comparison, country rankings, insight cards)
- Detailed ranking data per app
- Full timeline per developer
- Device market shares data per country
- Unlimited keyword tracking
AppBrain is an app data site, we track rankings, ratings, installs for all apps and games on Google Play and the App Store. AppBrain doesn't host app files or APKs, all install links go directly to the official store. All trademarks are owned by their respective owners.
More apps
App statistics
About AppBrain